Conference Coverage (ISV)

CTL Response Key to Malaria Vaccine

Published in Blood Weekly, September 22nd, 1997

The success of several experimental recombinant malaria vaccines depends on their ability to elicit cytotoxic lymphocytes (CTLs).

Most attempts to create a malaria vaccine have focussed on evoking antibodies capable of recognizing malaria parasite (Plasmodium yoelii) sporozoites. Parasites at this stage of the parasite's life cycle are highly sensitive to antibody neutralization.

But New York University researcher Moriya Tsuji noted that sporozoites injected into the bloodstream by the bite of an infected mosquito travel very rapidly to their target cells in the liver, giving antibodies only five minutes to do their job. He and co-workers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry